After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.
Editor's note: The Fierce team will be taking a publishing break for the holiday season and will not be sending its regular newsletters until the new year. We will return on Monday, January 5. We hope you enjoy your holidays, and we look forward to a bright 2015 in which we'll be ramping up our efforts to bring you the news you need. As always, thanks for reading!
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's vaccine assets among the benefits of a potential merger.
For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.
POPULAR COMMENT THREADS
Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.
China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.
More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.
A team from Finland has for the first time confirmed a link between GlaxoSmithKline's swine flu vaccine, Pandemrix, and narcolepsy.
So far, Sanofi's dengue candidate, the furthest along in the clinic, has struggled to ward off all four dengue viruses. But now, researchers have discovered new antibodies that could lead to a vaccine that does just that.
Baxter, prepping for a biopharma spinoff, has already revealed that vaccines won't figure into its plans going forward. And Monday, it took it second step to exit the space with a sale of its Vero technology and related assets.
From Our Sister Sites
In early 2013, Roche signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up the pieces, raising cash in hopes of submitting its drug to regulators this year.
HTG Molecular Diagnostics filed plans for a $60 million initial public offering to ramp up development for its next-generation molecular profiling technology and cash in on a growing market.